Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318580142> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W4318580142 endingPage "i618" @default.
- W4318580142 startingPage "i617" @default.
- W4318580142 abstract "Abstract Background Skin disorders as extra-intestinal manifestations of inflammatory bowel disease 9IBD) are well recognized. In addition, contribution of drugs used in IBD in development of skin cancers is now fully understood. However, there are increasing reports of drug induced immune skin disorders resulting from or contributed by anti TNF agents. We aim to describe the etiology, manifestations and therapeutic approaches of anti TNF induced skin eruptions from a large tertiary center cohort. Methods A prospective database of IBD patients receiving biologics for IBD was interrogated for those who developed skin eruptions following initiation of anti-TNF therapy. We excluded patients who had pre-existing skin manifestations. All patients had dermatological expert review and confirmation of diagnosis as drug induced skin disorder. We collected their disease characteristics, time interval from initiation of biologics to development of skin disorder, the putative causative agent and the treatment of the skin lesions Results Sixty-eight patients (median age= 30 years, Female 44, male 24) among 1478 patients who received at least one dose of biologics developed a drug induced immune skin disorder. Median duration to development of skin lesions was 7.5 months. Anti TNF agents were responsible for 88.5% of the skin lesions with the commonest lesions being psoriasiform lesions in 34 (50%) patients. In our cohort, the psoriasiform lesions were more prevalent in patients who used biosimilar anti-TNF agents compared to the originator agent (31 vs 3). Forty patients required cessation of anti TNF agents because of skin eruptions. Twenty-eight of these were switched to ustekinumab with resolution of skin eruptions in 27 patients. Conclusion Anti TNF induced psoariasiform skin lesions appear to be more prevalent in the biosimilar era. Half of these patients will need treatment switch; ustekinumab appears to be an effective option in these patients" @default.
- W4318580142 created "2023-01-31" @default.
- W4318580142 creator A5023755793 @default.
- W4318580142 creator A5028508269 @default.
- W4318580142 creator A5041049150 @default.
- W4318580142 date "2023-01-30" @default.
- W4318580142 modified "2023-09-29" @default.
- W4318580142 title "P487 Anti TNF induced psoariasiform skin eruptions are increasing in in the biosimilar era – a descriptive study of drug induced skin manifestations and their management" @default.
- W4318580142 doi "https://doi.org/10.1093/ecco-jcc/jjac190.0617" @default.
- W4318580142 hasPublicationYear "2023" @default.
- W4318580142 type Work @default.
- W4318580142 citedByCount "0" @default.
- W4318580142 crossrefType "journal-article" @default.
- W4318580142 hasAuthorship W4318580142A5023755793 @default.
- W4318580142 hasAuthorship W4318580142A5028508269 @default.
- W4318580142 hasAuthorship W4318580142A5041049150 @default.
- W4318580142 hasBestOaLocation W43185801421 @default.
- W4318580142 hasConcept C126322002 @default.
- W4318580142 hasConcept C137627325 @default.
- W4318580142 hasConcept C16005928 @default.
- W4318580142 hasConcept C2778260677 @default.
- W4318580142 hasConcept C2779134260 @default.
- W4318580142 hasConcept C2780035454 @default.
- W4318580142 hasConcept C2780564577 @default.
- W4318580142 hasConcept C59491497 @default.
- W4318580142 hasConcept C71924100 @default.
- W4318580142 hasConcept C72563966 @default.
- W4318580142 hasConcept C98274493 @default.
- W4318580142 hasConceptScore W4318580142C126322002 @default.
- W4318580142 hasConceptScore W4318580142C137627325 @default.
- W4318580142 hasConceptScore W4318580142C16005928 @default.
- W4318580142 hasConceptScore W4318580142C2778260677 @default.
- W4318580142 hasConceptScore W4318580142C2779134260 @default.
- W4318580142 hasConceptScore W4318580142C2780035454 @default.
- W4318580142 hasConceptScore W4318580142C2780564577 @default.
- W4318580142 hasConceptScore W4318580142C59491497 @default.
- W4318580142 hasConceptScore W4318580142C71924100 @default.
- W4318580142 hasConceptScore W4318580142C72563966 @default.
- W4318580142 hasConceptScore W4318580142C98274493 @default.
- W4318580142 hasIssue "Supplement_1" @default.
- W4318580142 hasLocation W43185801421 @default.
- W4318580142 hasOpenAccess W4318580142 @default.
- W4318580142 hasPrimaryLocation W43185801421 @default.
- W4318580142 hasRelatedWork W2799928618 @default.
- W4318580142 hasRelatedWork W2945043364 @default.
- W4318580142 hasRelatedWork W2955056766 @default.
- W4318580142 hasRelatedWork W3159932183 @default.
- W4318580142 hasRelatedWork W4200534430 @default.
- W4318580142 hasRelatedWork W4220693647 @default.
- W4318580142 hasRelatedWork W4294718754 @default.
- W4318580142 hasRelatedWork W4362578247 @default.
- W4318580142 hasRelatedWork W4376598430 @default.
- W4318580142 hasRelatedWork W4385476933 @default.
- W4318580142 hasVolume "17" @default.
- W4318580142 isParatext "false" @default.
- W4318580142 isRetracted "false" @default.
- W4318580142 workType "article" @default.